Healthy Clinical Trial
Official title:
A Phase 1, Open Label, Safety, Tolerability, and Pharmacokinetic Study of Tucatinib (ONT-380) in Healthy Japanese and Caucasian Subjects
Verified date | September 2019 |
Source | Seattle Genetics, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is being done to compare the pharmacokinetics (PK) and safety/tolerability of
tucatinib in healthy Japanese and Caucasian participants.
Three cohorts of healthy Japanese and Caucasian men and women will be admitted to the
Clinical Research Unit (CRU) and receive multiple oral doses of tucatinib over 14 days with
and without food.
Subjects will be in the study for up to 45 days, including the screening period.
Due to practical considerations, each cohort will be dosed sequentially (this is not a dose
escalation study).
Status | Completed |
Enrollment | 36 |
Est. completion date | August 4, 2019 |
Est. primary completion date | August 4, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - Body mass index between 18 and 32 kg/m^2 and a total body weight between 50 and 100 kg - In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead electrocardiograms, vital signs measurements, or clinical laboratory evaluations - Female subjects participating in the study will be of non-childbearing potential. Male subjects will be surgically sterile for at least 90 days or will agree to use contraception during the study and for 90 days after last dose of study drug. - Japanese subjects: 1. Must have been born in Japan 2. Must have 2 biological Japanese parents and 4 biological Japanese grandparents as confirmed by interview 3. Must have spent less than 10 years outside of Japan, and has no significant changes in lifestyle, including diet, since leaving Japan Exclusion Criteria: - Significant history of metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder - Current condition possibly affecting drug absorption - History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance - History of stomach or intestinal surgery or resection that would potentially alter absorption or excretion of orally administered drugs - History of alcoholism or drug/chemical abuse within 2 years of check-in - History of regular alcohol consumption exceeding 7 drinks/week for female subjects or 14 drinks/week for male subjects - Positive hepatitis panel and/or positive human immunodeficiency (HIV) test - Liver function tests, serum creatinine, hemoglobin, or hematocrit values outside of the normal reference range - Single 12-lead ECG demonstrating QTcF>450 msec for males or >470 msec for females - Participation in a clinical study involving administration of an investigational drug in the past 30 days from last dose or 5 half-lives (whichever is longer) - Use of any products known to alter drug absorption, metabolism or elimination processes, including St. John's wort and known strong inhibitors or inducers of CYP3A4 or CYP2C8, within 30 days - Use of or intention to use any prescription or nonprescription products, including vitamins, minerals and herbal preparations within 14 days - Use of tobacco- or nicotine-containing products within 3 months - Receipt of blood products within 2 months - Donation of blood from 56 days before the Screening Visit, plasma from 2 weeks before the Screening Visit or platelets from 6 weeks before the Screening Visit - Poor peripheral venous access - Have previously completed or withdrawn from this study or any other study investigating tucatinib and have previously received the study drug |
Country | Name | City | State |
---|---|---|---|
United States | PAREXEL International, Early Phase Clinical Unit - Los Angeles | Glendale | California |
Lead Sponsor | Collaborator |
---|---|
Seattle Genetics, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum observed concentration (Cmax) of tucatinib | 14 days | ||
Primary | Cmax of ONT-993 | 14 days | ||
Primary | Time of the maximum observed concentration (tmax) of tucatinib | 14 days | ||
Primary | Tmax of ONT-993 | 14 days | ||
Primary | AUC from time 0 to the time of last quantifiable concentration (AUClast) of tucatinib | 14 days | ||
Primary | AUClast of ONT-993 | 14 days | ||
Primary | AUC from time 0 to 12 hours postdose (AUC0-12hr) of tucatinib | 14 days | ||
Primary | AUC0-12hr of ONT-993 | 14 days | ||
Primary | AUC from time 0 extrapolated to infinity (AUC0-inf) of tucatinib | 1 day | ||
Primary | AUC from time 0 extrapolated to infinity (AUC0-inf) of ONT-993 | 1 day | ||
Primary | Percentage of AUC0-inf due to extrapolation (%AUCextrap) of tucatinib | 1 day | ||
Primary | %AUCextrap of ONT-993 | 1 day | ||
Primary | Apparent total clearance (CL/F) of tucatinib | 14 days | ||
Primary | Apparent volume of distribution during the terminal phase (Vz/F) of tucatinib | 14 days | ||
Primary | Metabolite-to-parent molar ratio based on AUC (MRAUC) of ONT-993 | 14 days | ||
Secondary | Incidence of adverse events (AEs) | 17 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |